SecBot SecBot
8-K ·Filed Sep 15, 2026

VERA

Vera Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed2mo ago SEC0001193125-26-391280
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

This is a best-case-scenario data readout that significantly de-risks the sBLA submission for full approval in Q4 2026. The combination of unprecedented efficacy (eGFR stabilization, 76% risk reduction) and a clean safety profile positions TRUTAKNA as a potential standard-of-care in IgAN. Traders should expect a strong positive reaction and monitor for analyst upgrades and increased institutional interest. The strong commercial launch metrics (350+ patient start forms in 10 weeks) provide additional near-term revenue visibility.

DirectionBullish
Confidencehigh
Horizonweeks

TRUTAKNA

▲ Bullish Named in this 8-K
Impact
Phase
Approved (Accelerated Approval)
Time to market
Already FDA-approved (July 7, 2026) — launched commercially; confirmatory full-approval data expected Q3 2026
Next catalyst
None dated

What to watchThe FDA approval is already priced in (modest +6.8% move on the day). The real binary catalysts ahead are the ORIGIN 3 eGFR confirmatory data (Q3 2026) and commercial launch execution metrics. Watch pricing/reimbursement decisions, early prescription uptake, and whether the confirmatory eGFR data supports full approval. The IgAN market is getting crowded (Tarpeyo, Filspari, Fabhalta, Vanrafia, Voyxact), so differentiation on convenience (at-home autoinjector) and upstream mechanism (dual BAFF/APRIL) will determine commercial success.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$33.67
T+0 close · Sep 15, 2026 · via day close
Latest settled
−20.43%
T+20 · $26.79 · next T+60 in 22d
Vs SPY
−23.41%
α at T+20
Latest observation
−10.84%
T+43 · FF3 residual α
  1. T+0 · Sep 15 $33.67entry
  2. T+1 · 2mo ago −6.33%α −6.65% · $31.54
  3. T+5 · 8w ago +0.98%α +0.16% · $34.00
  4. T+20 · 5w ago −20.43%α −23.41% · $26.79
  5. T+44 · todayOpen
  6. T+60 · in 22d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vera Therapeutics announced that TRUTAKNA (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis of the ORIGIN 3 Phase 3 trial in IgA nephropathy (IgAN). The drug demonstrated a 5.6 mL/min/1.73m2 placebo-adjusted difference in mean eGFR change at 52 weeks (p<0.0001), a 76% risk reduction in the composite kidney disease progression endpoint (HR 0.24, p<0.0001), and a favorable safety profile. The company plans to submit a supplemental BLA for full approval in Q4 2026, and reported strong commercial launch momentum with over 350 patient start forms generated in the first ten weeks. This is a transformative data readout that strongly supports the drug's disease-modifying potential and de-risks the path to full approval, representing a major positive catalyst for the stock.

Key Facts

  • TRUTAKNA met all prespecified endpoints in the ORIGIN 3 final efficacy analysis (n=428).
  • Placebo-adjusted difference in mean eGFR change from baseline at 52 weeks was 5.6 mL/min/1.73m2 (p<0.0001).
  • Annualized eGFR slope through 104 weeks showed a placebo-adjusted difference of 5.0 mL/min/1.73m2/year (p<0.0001).
  • 76% risk reduction in the composite kidney disease progression endpoint (HR 0.24, 95% CI 0.12-0.48, p<0.0001).
  • Zero dialysis, transplant, or death events in the TRUTAKNA arm vs. 8 in placebo through 104 weeks.
  • Company plans to submit supplemental BLA for full approval in Q4 2026.
  • Over 350 patient start forms generated in the first ten weeks of commercial launch.
  • Cash, cash equivalents, and marketable securities of ~$499M as of June 30, 2026, with additional $425M non-dilutive capital available through Oxford Facility.

Financial Impact

Transformative data supports full approval pathway for TRUTAKNA in IgAN, a potential $10B+ U.S. market opportunity. The 76% risk reduction in kidney disease progression and stabilization of eGFR at physiologic rates are best-in-class results that could drive significant market share and peak sales.

revenuemarket_shareregulatory_outcome

Risk Factors

  • Full FDA approval is not guaranteed and depends on the sBLA review process in 2027.
  • Competition from other IgAN therapies (e.g., sparsentan, iptacopan, other BAFF/APRIL inhibitors) could limit market share.
  • Commercial execution risk remains as the launch scales, including payer coverage and physician adoption.
  • The $425M Oxford Facility is subject to conditions and may not be fully accessible.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-391280
Document: d32300d8k.htm0001193125-26-391280
Document: d32300dex991.htm0001193125-26-391280
Document: 0001193125-26-391280-index-headers.html0001193125-26-391280
Document: 0001193125-26-391280-index.html0001193125-26-391280
Document: 0001193125-26-391280.txt0001193125-26-391280

Track record

25 reports on VERA

Performance horizon

12 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 13 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $26.97 −2.11% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.15 Now $26.97 −4.19% settles Nov 23
  4. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $26.97 −10.19% settles Nov 17
  5. Nov 5, 202611d ago 8-K Bullish 6/10 No price data
  6. Nov 5, 202611d ago Press Release Bullish 6/10 Entry $29.79 to $28.10 Now $26.97 −9.45% ▼ −5.66% −8.25% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $26.97 −15.64% ▼ −4.66% −3.75% vs SPY
  8. Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $26.97 −7.16% ▲ +5.09% +4.39% vs SPY
  9. Sep 15, 20268w ago 8-K Bullish 8/10 Viewing Entry $33.67 to $34.00 Now $26.97 −19.90% ▲ +0.98% +0.16% vs SPY
  10. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
Showing 10 of 25

US Market Status

Market Closed · Opens Wed (9h 32m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 15, 2026